Movano (NASDAQ:MOVE – Get Rating) and Soleno Therapeutics (NASDAQ:SLNO – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Analyst Ratings
This is a summary of current ratings and price targets for Movano and Soleno Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Movano | 0 | 0 | 0 | 0 | N/A |
| Soleno Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Soleno Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 123.46%. Given Soleno Therapeutics’ higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than Movano.
Volatility and Risk
Valuation and Earnings
This table compares Movano and Soleno Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Movano | N/A | N/A | -$30.33 million | ($0.92) | -1.14 |
| Soleno Therapeutics | N/A | N/A | -$24.07 million | ($3.29) | -1.09 |
Movano is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Movano and Soleno Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Movano | N/A | -174.30% | -139.89% |
| Soleno Therapeutics | N/A | -133.12% | -69.82% |
Insider & Institutional Ownership
20.2% of Movano shares are held by institutional investors. 7.5% of Movano shares are held by insiders. Comparatively, 23.7% of Soleno Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Soleno Therapeutics beats Movano on 7 of the 10 factors compared between the two stocks.
About Movano
Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medtech and consumer devices. Its platform uses radiofrequency technology, which enables the creation of sensors that are small enough to fit into wearable devices and other small form factors. The company develops Movano Ring that measures heart rate, heart rate variability, sleep, respiration, temperature, blood oxygen saturation, steps, and calories, as well as incorporates women-centric features and design. It is also developing non-invasive continuous glucose monitoring and cuffless blood pressure monitoring features to its technology platform. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.
About Soleno Therapeutics
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Receive News & Ratings for Movano Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Movano and related companies with MarketBeat.com's FREE daily email newsletter.
